Ras mutation and compositions and methods related thereto

Details Ras mutation and compositions and methods related thereto Ras mutation and compositions and methods related thereto

2007-03-09

2010-06-29

Sisson, Bradley L (Department: 1634)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C435S091200, C436S094000, C436S501000, C536S023500, C536S024310

Reexamination Certificate

active

07745128

ABSTRACT:
Disclosed are newly discovered Ras mutations and combinations of mutations, proteins and peptides and fusion proteins containing these mutations, nucleic acid molecules encoding such proteins, peptides, and fusion proteins, and a variety of tools and diagnostic, therapeutic, and screening methods associated with the use of such mutations.

REFERENCES:
patent: 4775622 (1988-10-01), Hitzeman et al.
patent: 5830463 (1998-11-01), Duke et al.
patent: 5847095 (1998-12-01), Bos et al.
patent: 5858378 (1999-01-01), Bostwick
patent: 5919651 (1999-07-01), Hitzeman et al.
patent: 5945306 (1999-08-01), Bandman et al.
patent: 5961978 (1999-10-01), Gaudernack et al.
patent: 6090546 (2000-07-01), Breivik et al.
patent: 6103477 (2000-08-01), Hillman et al.
patent: 7465454 (2008-12-01), Franzusoff et al.
patent: 2003/0035810 (2003-02-01), Caplan
patent: 2008/0069833 (2008-03-01), Franzusoff et al.
patent: 2009/0098154 (2009-04-01), Franzusoff et al.
patent: 2009/0142366 (2009-06-01), Franzusoff et al.
patent: 2009/0142367 (2009-06-01), Franzusoff et al.
patent: 2010/0034840 (2010-02-01), Apelian et al.
patent: 2486400 (1982-01-01), None
patent: WO 02/39951 (2002-05-01), None
patent: WO 2007/008780 (2007-01-01), None
patent: WO 2008/097863 (2008-08-01), None
Ricci et al., “A Case of Chronic Myelomonocytic Leukemia Progressing from Dysplastic to Proliferative Phenotype after Acquisition of a RAS Point Mutation,” Blood, vol. 106, No. 11, Nov. 16, 2005, 320B.
Supplementary European search report and Opinion for European Patent Application No. 07797163.8, mailed Oct. 19, 2009.
Sinai et al., “Enhancement of Resistance to Infectious Diseases by Oral Administration of Brewer's Yeast,” Infection and Immunity, vol. 9 No. 5, pp. 781-787 (May 1974).
Stubbs et al. “Whole recombinant yeast vaccine activates dendric cells and elicits protective cell-mediated immunity”, Nature Medicine May 2001, vol. 7, pp. 1-5.
Communication from the Examining Division for European Patent Application No. 07797163.8, mailed Jan. 28, 2010.
Abrams et al., “Mutant ras Epitopes as Targets for Cancer Vaccines”, Feb. 1996, vol. 23, abstract only.
Lu et al. “Mutation-Selective Tumor Remission with Ras-Targeted, Whole Yeast-Based Immunotherapy”, Cancer Research, Aug. 1, 2004, vol. 64, pp. 5084-5088.
Wittinghofer et al., “Three-Dimensional Structure of p21 in the Active Conformation and Analysis of an Oncogenic Mutant”, Environmental Health Perspectives, 1991, vol. 93, pp. 11-15.
Schleger et al., “The Role of Wild-Type and Mutated N-ras in the Malignant Transformation of Liver Cells”, Molecular Carcinogenesis, 2000, vol. 28, pp. 31-41.
Chen et al., “Comparison of the Average Structures, from Molecular Dynamics, of Complexes of GTPase Activating Protein (GAP) with Oncogenic and Wild-Type ras-p21: Identification of Potential Effector Domains”, Journal of Protein Chemistry, Jul. 2002, vol. 21, pp. 349-359.
Akagi et al., “Characterization of a Novel Oncogenic K-ras Mutation in Colon Cancer”, Biochemical and Biophysical Research Communications, 2007, vol. 352, pp. 728-732.
Bos, “ras Oncogenes in Human Cancer: A Review”, Cancer Research, Sep. 1, 1989, vol. 49, pp. 4682-4689.
Huncharek et al., “K-ras as a Prognostic Marker in Non-small Cell Lung Cancer: a Combined Analysis of 881 Cases”, Carcinogenesis, 1999, vol. 20, pp. 1507-1510.
Midgley and Kerr, “Ras as a Target in Cancer Therapy”, Critical Reviews in Oncology/Hematology, 2002, vol. 44, pp. 109-120.
Downward, “Targeting Ras Signalling Pathways in Cancer Therapy”, Nature Reviews, Jan. 2003, vol. 3, pp. 11-22.
Nielsen et al., “Sensitivity of Wild Type and Mutant ras Alleles to Ras Specific Exchange Factors: Identification of Factor Specific Requirements”, Oncogene, 2001, vol. 20, pp. 2091-2100.
Wu, Database DISSABS, on STN, AN 2001;14790, “Structural Analysis of Oncogenic H-ras Mutants G12A and G13A”, Masters Abstract International, 1999, vol. 38, p. 954, abstract.
Friday, “K-ras as a Target for Cancer Therapy”, Biochemica et Biophysica Acta, 2005, vol. 1756, pp. 127-144.
International Search Report and the Written Opinion of the International Search Authority, PCT Application No. PCT/US07/63711, filed Mar. 9, 2007, Applicant's Reference 3923-13-PCT.
International Preliminary Report on Patentability, PCT Application No. PCT/US07/63711, filed Mar. 9, 2007, Applicant's Reference 3923-13-PCT.
Franzusoff et al., “Yeasts encoding tumour antigens in cancer immunotherapy” Expert Opin. Biol. Ther. (2005) 5(4), pp. 565-575.

Affiliated with

Also associated with

Rating

Ras mutation and compositions and methods related thereto does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ras mutation and compositions and methods related thereto, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ras mutation and compositions and methods related thereto will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4243422